New York Times puts Avid’s Technology Front and Center

Posted by | June 24, 2010

Avid Radiopharmaceuticals was featured on the front page of The New York Times today. The article, “Promise Seen for Detection of Alzheimer’s,” by Gina Kolata (@ginakolata), highlights Avid’s advances in the early detection and early diagnosis of Alzheimer’s disease.

Avid will be announcing its complete findings of the company’s Phase III clinical trials on July 11, 2010 at the International Conference on Alzheimer’s Disease (ICAD) and expects to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) later this year.

We couldn’t be more proud of CEO Daniel M. Skovronsky, M.D., Ph.D., and the entire Avid team. Their development of amyloid imaging agent Florbetapir F 18 has the potential to be a “game changer” in the fight against Alzheimer’s disease. As the reporter writes, “[for] the first time doctors would have a reliable way to diagnose the presence of Alzheimer’s in patients with memory problems.”

Today’s article, coupled with The Wall Street Journal’s coverage in April, makes it clear that Avid’s advancements in the fight against Alzheimer’s is resonating.

(Visited 65 times, 1 visits today)

Tags: , , , , , ,